Literature DB >> 14999723

Evaluation of the protein binding ratio of drugs by a micro-scale ultracentrifugation method.

Daisuke Nakai1, Kazuyo Kumamoto, Chisa Sakikawa, Toshiyuki Kosaka, Taro Tokui.   

Abstract

Ultracentrifugation methods have been widely used for the determination of the free fraction of compounds in plasma, especially for lipophilic compounds. To estimate the effect of contaminated proteins in the "protein-free phase" fraction, 200 microL of human plasma was separated into three layers by ultracentrifugation at 436,000g for 140 min with a table-top ultracentrifuge. Twenty microliters of the middle layer was taken as the protein-free fraction. Major contaminated proteins were analyzed by liquid chromatography/electrospray ionization/tandem mass spectrometry (LC/ESI/MS/MS) and identified as albumin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein E, and apolipoprotein A-1. alpha-1-acid glycoprotein was not detected. Contamination of albumin was 0.13% of that in plasma. Simulation analysis demonstrated that at an actual free fraction of 1% (protein binding ratio of 99%), the extent of overestimation of free fraction was just 13% and the apparent free fraction was 1.13%. Human plasma protein binding ratios of 10 drugs estimated by this method correlated well with reported values determined by other methods, such as ultrafiltration and equilibrium dialysis, with a correlation factor of 0.98 and a slope of 0.99. Collectively, our results indicate the reliability of this micro-scale ultracentrifugation technique for the evaluation of the protein binding of drugs despite a little contamination of albumin. Copyright 2004 Wiley-Liss, Inc. and the American Pharmacists Association.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14999723     DOI: 10.1002/jps.20012

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  23 in total

1.  Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.

Authors:  C-C Peng; I Templeton; K E Thummel; C Davis; K L Kunze; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2011-04-13       Impact factor: 6.875

2.  Selective and brain penetrant neuropeptide y y2 receptor antagonists discovered by whole-cell high-throughput screening.

Authors:  Shaun P Brothers; S Adrian Saldanha; Timothy P Spicer; Michael Cameron; Becky A Mercer; Peter Chase; Patricia McDonald; Claes Wahlestedt; Peter S Hodder
Journal:  Mol Pharmacol       Date:  2009-10-16       Impact factor: 4.436

3.  Contributions of human cytochrome P450 enzymes to glyburide metabolism.

Authors:  Lin Zhou; Suresh B Naraharisetti; Li Liu; Honggang Wang; Yvonne S Lin; Nina Isoherranen; Jashvant D Unadkat; Mary F Hebert; Qingcheng Mao
Journal:  Biopharm Drug Dispos       Date:  2010-05       Impact factor: 1.627

4.  Influence of mild and moderate hepatic impairment on axitinib pharmacokinetics.

Authors:  Michael A Tortorici; Melvin Toh; S V Rahavendran; Robert R Labadie; Christine W Alvey; Thomas Marbury; Ernesto Fuentes; Matthew Green; Grace Ni; Brian Hee; Yazdi K Pithavala
Journal:  Invest New Drugs       Date:  2010-07-02       Impact factor: 3.850

5.  Physiologically Based Pharmacokinetic Model of All-trans-Retinoic Acid with Application to Cancer Populations and Drug Interactions.

Authors:  Jing Jing; Cara Nelson; Jisun Paik; Yoshiyuki Shirasaka; John K Amory; Nina Isoherranen
Journal:  J Pharmacol Exp Ther       Date:  2017-03-08       Impact factor: 4.030

6.  Modeling Therapeutic Antibody-Small Molecule Drug-Drug Interactions Using a Three-Dimensional Perfusable Human Liver Coculture Platform.

Authors:  Thomas J Long; Patrick A Cosgrove; Robert T Dunn; Donna B Stolz; Hisham Hamadeh; Cynthia Afshari; Helen McBride; Linda G Griffith
Journal:  Drug Metab Dispos       Date:  2016-09-12       Impact factor: 3.922

7.  Tacrolimus placental transfer at delivery and neonatal exposure through breast milk.

Authors:  Songmao Zheng; Thomas R Easterling; Karen Hays; Jason G Umans; Menachem Miodovnik; Shannon Clark; Justina C Calamia; Kenneth E Thummel; Danny D Shen; Connie L Davis; Mary F Hebert
Journal:  Br J Clin Pharmacol       Date:  2013-12       Impact factor: 4.335

8.  Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo.

Authors:  I E Templeton; K E Thummel; E D Kharasch; K L Kunze; C Hoffer; W L Nelson; N Isoherranen
Journal:  Clin Pharmacol Ther       Date:  2007-05-09       Impact factor: 6.875

9.  Albumin-Mediated Uptake Improves Human Clearance Prediction for Hepatic Uptake Transporter Substrates Aiding a Mechanistic In Vitro-In Vivo Extrapolation (IVIVE) Strategy in Discovery Research.

Authors:  Na Li; Akshay Badrinarayanan; Kazuya Ishida; Xingwen Li; John Roberts; Shuai Wang; Mike Hayashi; Anshul Gupta
Journal:  AAPS J       Date:  2020-11-16       Impact factor: 4.009

10.  Pharmacokinetics of tacrolimus during pregnancy.

Authors:  Songmao Zheng; Thomas R Easterling; Jason G Umans; Menachem Miodovnik; Justina C Calamia; Kenneth E Thummel; Danny D Shen; Connie L Davis; Mary F Hebert
Journal:  Ther Drug Monit       Date:  2012-12       Impact factor: 3.681

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.